Biologics (BIO)

PII-001 - APPROVED THERAPEUTIC PROTEINS WITH CHALLENGES IN CLINICAL ENDPOINTS EVALUATION WHERE PHARMACODYNAMIC BIOMARKERS MAY IMPROVE EFFICIENCY OF BIOSIMILAR DEVELOPMENT

PII-002 - DEVELOPMENT OF A TRANSLATION PK-PD MODEL FOR IN VIVO CAR-T CELL THERAPIES USING CAR MRNA LOADED POLYMERIC NANOPARTICLE VECTOR

PII-003 - EVALUATION OF DRUG-DRUG INTERACTION (DDI) POTENTIAL FOLLOWING EPCORITAMAB TREATMENT: RESULTS FROM EXPANSION OF A PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODEL.

PII-004 - MODEL-BASED REPRIMING WINDOW SELECTION FOR SUBCUTANEOUS EPCORITAMAB.